Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 17 | 2025 | 969 | 2.380 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 102 | 1.160 |
Why?
|
| Mammography | 5 | 2023 | 168 | 1.060 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 21 | 0.830 |
Why?
|
| Contrast Media | 5 | 2021 | 9 | 0.770 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 243 | 0.670 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 13 | 0.590 |
Why?
|
| Biopsy | 4 | 2017 | 82 | 0.510 |
Why?
|
| Retrospective Studies | 13 | 2023 | 2415 | 0.490 |
Why?
|
| Trauma Centers | 1 | 2015 | 6 | 0.460 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 24 | 0.460 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 42 | 0.450 |
Why?
|
| Breast | 5 | 2023 | 84 | 0.400 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 384 | 0.390 |
Why?
|
| Female | 19 | 2025 | 12396 | 0.380 |
Why?
|
| Humans | 23 | 2025 | 17314 | 0.370 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 1 | 0.360 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 2 | 0.330 |
Why?
|
| Early Detection of Cancer | 2 | 2025 | 529 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2023 | 203 | 0.290 |
Why?
|
| Ultrasonography, Mammary | 2 | 2018 | 4 | 0.260 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 21 | 0.240 |
Why?
|
| Precision Medicine | 1 | 2025 | 29 | 0.230 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 8 | 0.230 |
Why?
|
| Middle Aged | 11 | 2025 | 7836 | 0.210 |
Why?
|
| Image Enhancement | 2 | 2021 | 3 | 0.210 |
Why?
|
| Hydronephrosis | 1 | 2023 | 2 | 0.200 |
Why?
|
| Ureteral Calculi | 1 | 2023 | 2 | 0.200 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 24 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2023 | 2514 | 0.190 |
Why?
|
| Algorithms | 1 | 2023 | 223 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 75 | 0.180 |
Why?
|
| Adult | 10 | 2025 | 7500 | 0.170 |
Why?
|
| Neodymium | 1 | 2020 | 1 | 0.170 |
Why?
|
| Magnetic Phenomena | 1 | 2020 | 1 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 298 | 0.170 |
Why?
|
| Aged | 9 | 2025 | 6084 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2019 | 2 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2020 | 1226 | 0.160 |
Why?
|
| Echo-Planar Imaging | 1 | 2019 | 1 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 44 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 184 | 0.150 |
Why?
|
| Telemedicine | 1 | 2022 | 181 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2023 | 342 | 0.150 |
Why?
|
| Foreign Bodies | 1 | 2018 | 1 | 0.140 |
Why?
|
| Surgical Instruments | 1 | 2018 | 2 | 0.140 |
Why?
|
| Parenchymal Tissue | 1 | 2017 | 1 | 0.140 |
Why?
|
| Radiologists | 1 | 2016 | 4 | 0.130 |
Why?
|
| Calcinosis | 1 | 2016 | 35 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2016 | 52 | 0.130 |
Why?
|
| Risk Factors | 3 | 2025 | 3258 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 338 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 535 | 0.120 |
Why?
|
| Boston | 1 | 2015 | 28 | 0.120 |
Why?
|
| Utilization Review | 1 | 2015 | 42 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 48 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 312 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 1925 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 1160 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 15 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2012 | 252 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2023 | 1098 | 0.080 |
Why?
|
| Time Factors | 1 | 2012 | 1039 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 357 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 372 | 0.050 |
Why?
|
| Breast Density | 1 | 2023 | 31 | 0.050 |
Why?
|
| Young Adult | 2 | 2021 | 2465 | 0.050 |
Why?
|
| Reoperation | 1 | 2021 | 23 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 6 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2025 | 1076 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 76 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 44 | 0.040 |
Why?
|
| Eating | 1 | 2020 | 34 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 81 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| Angiography | 1 | 2019 | 12 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2019 | 8 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 1 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 19 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2019 | 9 | 0.040 |
Why?
|
| Trastuzumab | 1 | 2019 | 19 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2019 | 33 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 145 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 79 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 99 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 114 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 153 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1266 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 36 | 0.030 |
Why?
|
| Health Facilities | 1 | 2016 | 16 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 90 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 460 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 55 | 0.030 |
Why?
|
| Male | 2 | 2021 | 9804 | 0.030 |
Why?
|
| Iopamidol | 1 | 2012 | 1 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2012 | 1 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 7 | 0.020 |
Why?
|
| Software | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 672 | 0.020 |
Why?
|
Concepts
(101)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->